Xintela マネジメント

マネジメント基準チェック /24

Xintela'sの CEO はEvy Lundgren-Åkerlundで、 Jan2009年に任命され、の在任期間は 15.42年です。の年間総報酬はSEK 4.59Mで、 41%給与と59%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.2%を直接所有しており、その価値はSEK 1.75M 。経営陣と取締役会の平均在任期間はそれぞれ11.4年と2.9年です。

主要情報

Evy Lundgren-Åkerlund

最高経営責任者

SEK 4.6m

報酬総額

CEO給与比率	41.0%
CEO在任期間	15.8yrs
CEOの所有権	1.2%
経営陣の平均在職期間	11.8yrs
取締役会の平均在任期間	3.3yrs

経営陣の近況

Recent updates

Calculating The Fair Value Of Xintela AB (publ) (STO:XINT)

Nov 04

CEO報酬分析

Xintela の収益と比較して、Evy Lundgren-Åkerlund の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-SEK 41m
Mar 31 2024	n/a	n/a	-SEK 49m
Dec 31 2023	SEK 5m	SEK 2m	-SEK 54m
Sep 30 2023	n/a	n/a	-SEK 59m
Jun 30 2023	n/a	n/a	-SEK 65m
Mar 31 2023	n/a	n/a	-SEK 66m
Dec 31 2022	SEK 4m	SEK 2m	-SEK 66m
Sep 30 2022	n/a	n/a	-SEK 67m
Jun 30 2022	n/a	n/a	-SEK 68m
Mar 31 2022	n/a	n/a	-SEK 64m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 60m
Sep 30 2021	n/a	n/a	-SEK 68m
Jun 30 2021	n/a	n/a	-SEK 60m
Mar 31 2021	n/a	n/a	-SEK 54m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 50m
Sep 30 2020	n/a	n/a	-SEK 40m
Jun 30 2020	n/a	n/a	-SEK 40m
Mar 31 2020	n/a	n/a	-SEK 42m
Dec 31 2019	SEK 3m	SEK 1m	-SEK 44m
Sep 30 2019	n/a	n/a	-SEK 37m
Jun 30 2019	n/a	n/a	-SEK 33m
Mar 31 2019	n/a	n/a	-SEK 28m
Dec 31 2018	SEK 3m	SEK 1m	-SEK 26m
Sep 30 2018	n/a	n/a	-SEK 24m
Jun 30 2018	n/a	n/a	-SEK 25m
Mar 31 2018	n/a	n/a	-SEK 24m
Dec 31 2017	SEK 3m	SEK 1m	-SEK 22m

報酬と市場: Evyの総報酬 ($USD 436.43K ) は、 Swedish市場 ($USD 257.03K ) の同規模の企業の平均を上回っています。

報酬と収益: Evyの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Evy Lundgren-Åkerlund (67 yo)

15.8yrs

在職期間

SEK 4,589,000

報酬

Dr. Evy Lundgren-Åkerlund, BSc, Ph D, Assoc Prof, serves as Chief Executive Officer at Xintela AB (publ) and has been its Executive Director since 2009. Dr. Lundgren-Åkerlund had been the Chief Executive O...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Gregory Batcheller	Executive Chairman of the Board	13.8yrs	SEK 383.00k	0.80% SEK 2.0m
Evy Lundgren-Åkerlund	Chief Executive Officer	15.8yrs	SEK 4.59m	1.23% SEK 3.1m
Gunnar Telhammar	CFO & Finance Director	11.8yrs	データなし	0.073% SEK 183.6k
Lucienne Vonk	Chief Scientific Officer	less than a year	データなし	データなし
Per Goran Norlen	Chief Medical Officer	2yrs	データなし	データなし
Camilla Wennersten	Director of Clinical Development	no data	データなし	0.0016% SEK 4.0k

11.8yrs

平均在職期間

65yo

平均年齢

経験豊富な経営陣: XINTの経営陣は経験豊富で経験豊富です（平均在職期間は11.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Gregory Batcheller	Executive Chairman of the Board	13.8yrs	SEK 383.00k	0.80% SEK 2.0m
Thomas Eldered	Director	1.9yrs	SEK 17.00k	データなし
Lars Hedbys	Independent Director	3.3yrs	SEK 197.00k	0.064% SEK 162.0k
Hans-Joachim Simons	Director	2.4yrs	SEK 99.00k	データなし
Maarten de Chateau	Independent Director	3.8yrs	SEK 197.00k	0.43% SEK 1.1m

3.3yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: XINTの取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

Xintela マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Xintela Appoints Lucienne Vonk as Chief Scientific Officer

Less than half of directors are independent

Xintela AB (Publ) Appoints Peter Ekolind as Acting CEO, Effective October 1, 2022

Less than half of directors are independent

Chief Executive Officer recently bought kr116k worth of stock

CFO & Finance Director recently bought kr51k worth of stock

Recent updates

New major risk - Share price stability

New major risk - Negative shareholders equity

Xintela AB (publ) to Report Q1, 2024 Results on May 24, 2024

Xintela Appoints Lucienne Vonk as Chief Scientific Officer

Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study

New major risk - Shareholder dilution

Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study

Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study

Xintela AB (publ) Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress

Less than half of directors are independent

Xintela Starts Next Dose Level of Xstem in Knee Osteoarthritis Clinical Study

Calculating The Fair Value Of Xintela AB (publ) (STO:XINT)

Xintela Completes Dosing of Xstem First Dose Level in Knee Osteoarthritis Clinical Study

Xintela AB (Publ) Appoints Peter Ekolind as Acting CEO, Effective October 1, 2022

Xintela AB (publ) Starts Clinical Study with XSTEM for Difficult-To-Heal Leg Ulcers

Xintela Receives Approval for Clinical Study with XSTEM on Difficult-to-Heal Venous Leg Ulcers

Less than half of directors are independent

Xintela Starts Clinical Study of XSTEM® in Knee Osteoarthritis

Xintela AB (Publ) Receives Grant of 4.8 Million SEK from Vinnova

Xintela Signs Agreement with CRO for Phase I/II study

Chief Executive Officer recently bought kr116k worth of stock

CFO & Finance Director recently bought kr51k worth of stock

Xintela AB (Publ) Receives Permission from the Medical Products Agency to Produce Cell Therapy Products

Xintela to Develop Stem Cell Therapy for Difficult-To-Heal Wounds

Xintela AB (publ) Publishes Results from Glioblastoma Antibody Study

New 90-day low: kr2.96

Full year 2020 earnings released: kr0.68 loss per share (vs kr1.10 loss in FY 2019)

Xintela AB (publ) to Report Q1, 2021 Results on May 21, 2021

Xintela AB (publ) Receives Notice of Allowance from USPTO for the Treatment of Brain Tumors

Xintela Recruits Jeffrey Abbey to Targinta as Senior Management Advisor

Xintela AB (publ) to Report Fiscal Year 2020 Results on Feb 26, 2021

Xintela AB (Publ) Appoints Lars Hedbys to Its Board of Directors

New 90-day low: kr2.98

Xintela Announces Promising Results of Human Stem Cells XSTEM in Preclinical Acute Respiratory Distress Syndrome Study

New 90-day low: kr3.78

Xintela AB (publ) to Report Nine Months, 2020 Results on Nov 27, 2020

Xintela AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 36.70987 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24